26 April 2025, Boston— Chronic thromboembolic pulmonary hypertension (CTEPH) often goes undiagnosed for years, is frequently caught late, and primarily affects young, otherwise healthy individuals. Even when diagnosed, finding the right treatment can be challenging.
At this year’s Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), a day-long CTEPH conference—co-sponsored by ISHLT and the International CTEPH Association (ICA) —brought together worldwide experts who presented ground-breaking outcomes research on treatments for the disease.
“In the past, patients with CTEPH were, on average, misdiagnosed for several years,” said presenter Michael M. Madani, MD, FACS, Executive Director-Surgery, UC San Diego Health Cardiovascular Institute and co-chair of the CTEPH conference. “Due to educational events like this, it’s down to about 12-18 months.
“Unfortunately, we still see patients who’ve been treated for asthma, COPD, and obesity for years before someone considers CTEPH,” he said.
The session covered new medications, refined treatment techniques, innovative treatment approaches, and case-based clinical decision-making.
Key takeaways
The Cause of CTEPH
CTEPH Diagnosis
CTEPH by the Numbers
END
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy. ISHLT members focus on transplantation and a range of interventions and therapies related to advanced heart and lung disease.
The ISHLT Annual Meeting and Scientific Sessions will be held from 27-30 April at the John B. Hynes Veterans Memorial Convention Center in Boston.
Contact:
Jess Burke, Director of Marketing and Communications
+1.312.224.0015
jess.burke@ishlt.org